• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Study: No benefit for biological mesh in hernia repair

Study: No benefit for biological mesh in hernia repair

January 29, 2016 By Fink Densford

JAMAUsing biologic mesh for abdominal wall hernia repair provides no benefit over using cheaper synthetic mesh, according to a new study from the UT Southwestern Medical Center that compared the 2 materials.

Findings from the study were reported earlier this week in JAMA Surgery.

“In the absence of evidence demonstrating superiority of biological mesh materials, the expense associated with their use cannot be justified,” study author Dr. Sergio Huerta of UT Southwestern said in a press release.

Meshes are used during abdominal hernia repairs, and biological meshes were introduced in the 1990s in hopes of reducing the rate of infections erosions associated with earlier synthetic meshes. Biologic meshes are derived from biological sources, such as pig or cow tissue, and cost on average 350% more than synthetic mesh, according to a UT Southwestern press release.

The study examined 274 published articles covering the use of biologic mesh in abdominal wall hernia repair, as well as the FDA 510(k) approvals of the devices. FDA clearance for the meshes was based on “substantial equivalence” to synthetic meshes, rather than clinical trials.

Outcomes for 1,033 patients were analyzed during the study, which found that follow-up time, operative technique, meshes used and patient selection criteria varied widely, and outcomes such as infection were inconsistently reported across all studies.

The re-examination analysis found only 3 studies which compared biologic meshes to synthetics, none of which were randomized clinical trials. In addition, 16 of 20 studies did not report conflicts of interest and recurrence rates ranged from 0% to 80%.

“The cost of health care is increasing at a pace much greater than the economy can support. Much of the increase in health care expenses has been attributed to the use of new technologies. It is believed that greater application of evidence-based medicine will help control these increasing costs. The use of biological mesh materials for hernia repair is one of many examples in which significant costs could be avoided by tailoring clinical practice based on careful review of the evidence. These devices were approved on the basis of being equivalent to other devices, which cost as much as one-fourth less than the biological equivalent. Until evidence exists demonstrating superiority of biological mesh materials, the expense associated with their use cannot be justified,” study authors wrote.

Filed Under: Clinical Trials, Surgical Tagged With: Journal of the American Medical Assn. (JAMA)

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy